- MYND Life Sciences (MYND) has announced plans to undertake a non-brokered private placement to raise gross proceeds of up to $3,500,000
- Proceeds of the offering will be used to advance the company’s novel drug discovery platform and commercialize its diagnostic business unit
- MYND Life Sciences is a medical biotech drug research and development company
- MYND Life Sciences Inc. (MYND) opened trading at C$0.12 per share
MYND Life Sciences (MYND) has announced plans to undertake a non-brokered private placement to raise gross proceeds of up to $3,500,000.
The offering will close immediately after the closing of MYND’s acquisition of Tidal Care Inc.
All shares issued are subject to a statutory four-month hold period. The offering is subject to final acceptance by the Canadian Securities Exchange.
Proceeds of the offering will be used to advance the company’s novel drug discovery platform, commercialize its diagnostic business unit and for general working capital.
MYND Life Sciences is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development and diagnostics.
MYND Life Sciences Inc. (MYND) opened trading at C$0.12 per share.
